Compare Quest Diagnostics Inc (DGX) vs Herbalife Nutrition Ltd (HLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Herbalife Nutrition Ltd — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while Herbalife Nutrition Ltd trades at $11.76 (market cap $1.23B). The key difference: Quest Diagnostics Inc is far larger — about 21.3× Herbalife Nutrition Ltd's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Herbalife Nutrition Ltd pays none. Which is the better fit depends on your goals.
| DGX | HLF | |
|---|---|---|
Market Cap | $26.21B | $1.23B |
Sector | Health | Consumer Staples |
52-Week High | $238.50 | $19.96 |
52-Week Low | $173.49 | $7.75 |
Enterprise Value | $31.97B | $3.06B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Herbalife (HLF) trades at $11.695, up 1.52% on the day, with a bearish technical outlook per moving averages. The company reported Q2 2026 net sales of $1.3 billion, a 5.4% year-over-year increase, though EPS of $0.51 missed estimates. Valuation ratios appear attractive with a P/E of 7.53 and P/S of 0.24. Positive news includes being named to TIME's America's Best Companies 2026 list, but a planned CFO transition in December 2026 introduces uncertainty.
The outlook is mixed; strong sales growth and low valuation metrics offer potential upside, but recent earnings misses, a high debt load, and negative shareholder equity pose significant risks. Analyst consensus leans bullish with 53.84% buy ratings, yet the stock faces headwinds from competitive pressures and margin volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →
